Urinary arsenic metabolism in a Western Chinese population exposed to high-dose inorganic arsenic in drinking water: Influence of ethnicity and genetic polymorphisms

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 117-123

  Fu, Songbo ^a   Wu, Jie ^a   Li, Yuanyuan ^a   Liu, Yan ^a   Gao, Yanhui ^a   Yao, Feifei ^a   Qiu, Chuanying ^b   Song, Li ^a   Wu, Yu ^a   Liao, Yongjian ^c   Sun, Dianjun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GANSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Arsenic; AS3MT; Genetic polymorphism; GSTO1; GSTO2; Methylation metabolism

Indexed keywords

ARSENIC; DRINKING WATER; GLUTATHIONE S TRANSFERASE OMEGA 1; GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AS3MT GENE; BLOOD SAMPLING; CHILD; CHINESE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ETHNICITY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; GSTO1 GENE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METABOLISM; NEWBORN; OXIDATION; PRESCHOOL CHILD; SCHOOL CHILD; SKIN DEFECT; URINALYSIS; WATER SUPPLY;

EID: 84889582012     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.11.004     Document Type: Article

References (52)

1. Agusa T., Iwata H., Fujihara J., Kunito T., Takeshita H., Minh T.B., Trang P.T., Viet P.H., Tanabe S. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol. 2009, 236:131-141.
2. Aposhian H.V., Zheng B., Aposhian M.M., Le X.C., Cebrian M.E., Cullen W., Zakharyan R.A., Ma M., Dart R.C., Cheng Z., Andrewes P., Yip L., O'Malley G.F., Maiorino R.M., Van Voorhies W., Healy S.M., Titcomb A. DMPS-arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine. Toxicol. Appl. Pharmacol. 2000, 165:74-83.
3. Chen Y.C., Xu L., Guo Y.L., Su H.J., Hsueh Y.M., Smith T.J., Ryan L.M., Lee M.S., Chaor S.C., Lee J.Y., Christiani D.C. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 2003, 38:201-211.
4. Chen C.J., Hsu L.I., Wang C.H., Shih W.L., Hsu Y.H., Tseng M.P., Lin Y.C., Chou W.L., Chen C.Y., Lee C.Y., Wang L.H., Cheng Y.C., Chen C.L., Chen S.Y., Wang Y.H., Hsueh Y.M., Chiou H.Y., Wu M.M. Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan. Toxicol. Appl. Pharmacol. 2005, 206:198-206.
5. Chen B., Arnold L.L., Cohen S.M., Thomas D.J., Le X.C. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol. Sci. 2011, 124:320-326.
6. Chowdhury U.K., Rahman M.M., Sengupta M.K., Lodh D., Chanda C.R., Roy S., Quamruzzaman Q., Tokunaga H., Ando M., Chakraborti D. Pattern of excretion of arsenic compounds [arsenite, arsenate, MMA(V), DMA(V)] in urine of children compared to adults from an arsenic exposed area in Bangladesh. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 2003, 38:87-113.
7. Chung J.S., Kalman D.A., Moore L.E., Kosnett M.J., Arroyo A.P., Beeris M., Mazumder D.N., Hernandez A.L., Smith A.H. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ. Health Perspect. 2002, 110:729-733.
8. Chung W.H., Sung B.H., Kim S.S., Rhim H., Kuh H.J. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int. J. Oncol. 2009, 34:1669-1679.
9. De Chaudhuri S., Ghosh P., Sarma N., Majumdar P., Sau T.J., Basu S., Roychoudhury S. Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ. Health Perspect. 2008, 116:501-505.
10. Del R.L.M., Styblo M., Cullen W.R., Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 2001, 174:282-293.
11. Drobna Z., Waters S.B., Walton F.S., LeCluyse E.L., Thomas D.J., Styblo M. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 201:166-177.
12. Drobna Z., Waters S.B., Devesa V., Harmon A.W., Thomas D.J., Styblo M. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol. Appl. Pharmacol. 2005, 207:147-159.
13. Drobna Z., Naranmandura H., Kubachka K.M., Edwards B.C., Herbin-Davis K., Styblo M., Le X.C., Creed J.T., Maeda N., Hughes M.F., Thomas D.J. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol. 2009, 22:1713-1720.
14. Fu S., Wu J., Chen F., Sun D., Fu S. Polymorphisms of glutathione S-transferases omega-1 among ethnic populations in China. BMC Genet. 2008, 9:29.
15. Gong Z., Lu X., William R.C., Le X.C. Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. At. Spectrom. 2001, 16:1409-1413.
16. IARC IARC monographs on the evaluation of carcinogenic risks to humans. Some Drinking-water Disinfectants and Contaminants, Including Arsenic 2004, 84:512. IARC Press, Lyon.
17. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 2001, 172:249-261.
18. Kligerman A.D., Tennant A.H. Insights into the carcinogenic mode of action of arsenic. Toxicol. Appl. Pharmacol. 2007, 222:281-288.
19. Le X.C., Ma M. Short-column liquid chromatography with hydride generation atomic fluorescence detection for the speciation of arsenic. Anal. Chem. 1998, 70:1926-1933.
20. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 2000, 72:5172-5177.
21. Le X.C., Ma M., Cullen W.R., Aposhian H.V., Lu X., Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 2000, 108:1015-1018.
22. Lindberg A.L., Rahman M., Persson L.A., Vahter M. The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. Toxicol. Appl. Pharmacol. 2008, 230:9-16.
23. Loffredo C.A., Aposhian H.V., Cebrian M.E., Yamauchi H., Silbergeld E.K. Variability in human metabolism of arsenic. Environ. Res. 2003, 92:85-91.
24. Mandal B.K., Ogra Y., Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 2001, 14:371-378.
25. Marnell L.L., Garcia-Vargas G.G., Chowdhury U.K., Zakharyan R.A., Walsh B., Avram M.D., Kopplin M.J., Cebrian M.E., Silbergeld E.K., Aposhian H.V. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem. Res. Toxicol. 2003, 16:1507-1513.
26. Meza M.M., Kopplin M.J., Burgess J.L., Gandolfi A.J. Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico. Environ. Res. 2004, 96:119-126.
27. Meza M., Gandolfi A.J., Klimecki W.T. Developmental and genetic modulation of arsenic biotransformation: a gene by environment interaction. Toxicol. Appl. Pharmacol. 2007, 222:381-387.
28. Naranmandura H., Rehman K., Le X.C., Thomas D.J. Formation of methylated oxyarsenicals and thioarsenicals in wild-type and arsenic (+3 oxidation state) methyltransferase knockout mice exposed to arsenate. Anal. Bioanal. Chem. 2013, 405:1885-1891.
29. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Vasken A.H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 2000, 163:203-207.
30. Qiu C.Y., Gao Y.H., Fu S.B., Song L., Wu Y., Zheng Z.Y., Sun D.J. Epidemiological study on the effect of drinking water endemic arsenism. Chin. J. Endemiol. 2010, 29:70-73.
31. Schlawicke Engstrom K., Broberg K., Concha G., Nermell B., Warholm M., Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect. 2007, 115:599-605.
32. Schmuck E.M., Board P.G., Whitbread A.K., Tetlow N., Cavanaugh J.A., Blackburn A.C., Masoumi A. Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Pharmacogenet. Genomics 2005, 15:493-501.
33. Schwerdtle T., Walter I., Mackiw I., Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 2003, 24:967-974.
34. Smith A.H., Lingas E.O., Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull. World Health Organ. 2000, 78:1093-1103.
35. Steinmaus C., Bates M.N., Yuan Y., Kalman D., Atallah R., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Hoang B.K., Smith A.H. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J. Occup. Environ. Med. 2006, 48:478-488.
36. Thomas D.J., Waters S.B., Styblo M. Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 2004, 198:319-326.
37. Tseng C.H. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2007, 25:1-22.
38. Tseng C.H., Huang Y.K., Huang Y.L., Chung C.J., Yang M.H., Chen C.J., Hsueh Y.M. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol. 2005, 206:299-308.
39. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. Sci. Prog. 1999, 82:69-88.
40. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181-182:211-217.
41. Valenzuela O.L., Borja-Aburto V.H., Garcia-Vargas G.G., Cruz-Gonzalez M.B., Garcia-Montalvo E.A., Calderon-Aranda E.S., Del R.L.M. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ. Health Perspect. 2005, 113:250-254.
42. Valenzuela O.L., Drobna Z., Hernandez-Castellanos E., Sanchez-Pena L.C., Garcia-Vargas G.G., Borja-Aburto V.H., Styblo M., Del R.L.M. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol. Appl. Pharmacol. 2009, 239:200-207.
43. Wade T.J., Xia Y., Wu K., Li Y., Ning Z., Le X.C., Lu X., Feng Y., He X., Mumford J.L. Increased mortality associated with well-water arsenic exposure in Inner Mongolia, China. Int. J. Environ. Res. Public Health 2009, 6:1107-1123.
44. Wang Z., Zhou J., Lu X., Gong Z., Le X.C. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem. Res. Toxicol. 2004, 17:95-103.
45. Whitbread A.K., Tetlow N., Eyre H.J., Sutherland G.R., Board P.G. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 2003, 13:131-144.
46. WHO Arsenic and arsenic compounds. Environmental Health Criteria 2001, 224. 2nd ed.
47. WHO Background document for preparation of WHO Guidelines for drinking-water quality. Arsenic in Drinking-water 2003, (WHO/SDE/WSH/03.04/75).
48. Wood T.C., Salavagionne O.E., Mukherjee B., Wang L., Klumpp A.F., Thomae B.A., Eckloff B.W., Schaid D.J., Wieben E.D., Weinshilboum R.M. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem. 2006, 281:7364-7373.
49. Xia Y., Wade T.J., Wu K., Li Y., Ning Z., Le X.C., He X., Chen B., Feng Y., Mumford J.L. Well water arsenic exposure, arsenic induced skin-lesions and self-reported morbidity in Inner Mongolia. Int. J. Environ. Res. Public Health 2009, 6:1010-1025.
50. Yu R.C., Hsu K.H., Chen C.J., Froines J.R. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomarkers Prev. 2000, 9:1259-1262.
51. Yu L., Kalla K., Guthrie E., Vidrine A., Klimecki W.T. Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms in European and indigenous Americans. Environ. Health Perspect. 2003, 111:1421-1427.
52. Zakharyan R.A., Sampayo-Reyes A., Healy S.M., Tsaprailis G., Board P.G., Liebler D.C., Aposhian H.V. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 2001, 14:1051-1057.